Home Blog Page 257

KPJ Healthcare Launches First Orthopaedic and Rheumatology Centre of Excellence Under the KPJ Health System

By
Advertorial Desk
-

BUKIT MERTAJAM, Malaysia, Aug. 3, 2026 /PRNewswire/ — KPJ Healthcare Berhad (“KPJ Healthcare” or “the Group”) today launched its first Orthopaedic and Rheumatology Centre of Excellence (“CoE”) at KPJ Penang Specialist Hospital (“KPJ Penang”), marking the third CoE under the KPJ Health System (“KPJHS”). As Malaysia’s first private integrated academic health system, the Group continues to advance specialised musculoskeletal and joint care through the integration of Practice, Education, Research and Innovation.

YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJ Health System Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation (seated, centre), together with KPJ Healthcare Berhad’s Board of Directors and senior management team as well as KPJ Penang Specialist Hospital’s Consultant Team at the launch of the hospital’s Orthopaedic & Rheumatology Centre of Excellence.
YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJ Health System Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation (seated, centre), together with KPJ Healthcare Berhad’s Board of Directors and senior management team as well as KPJ Penang Specialist Hospital’s Consultant Team at the launch of the hospital’s Orthopaedic & Rheumatology Centre of Excellence.

Designed to support the management of complex conditions, the Orthopaedic and Rheumatology CoE integrates orthopaedic subspecialties, rheumatology and multidisciplinary expertise such as rehabilitation within a coordinated model of care. Bringing together consultations, diagnostic imaging, treatment rooms and advanced rehabilitation together on a single floor, the Centre provides a more seamless patient experience from diagnosis through rehabilitation and recovery. Comprehensive services include general orthopaedics, spine surgery, arthroplasty (joint replacement), arthroscopy and sports surgery, foot and ankle surgery, hand and microsurgery, paediatric orthopaedics, trauma and fracture management, rheumatology and pain services.

Its capabilities are further enhanced by AI-assisted robotic joint replacement surgery, computer-assisted navigation and minimally invasive surgical techniques, supporting greater surgical precision, improved mobility and faster functional recovery. Supporting these capabilities are tailored rehabilitation programmes, including post-spine surgery, post-sports injury and paediatric orthopaedic rehabilitation, supported by specialised technologies such as an anti-gravity treadmill.

YBhg. Datuk Syed Mohamed Syed Ibrahim, Chairman of the KPJHS Governing Council, Chairman of KPJ Healthcare University Sdn. Bhd. and President & Chief Executive of Johor Corporation (“JCorp”) said, “Our ambition for every Centre of Excellence in the KPJ Health System, including the one we launch today, is not that it should remain a Centre in perpetuity. Our ambition is for it to continue growing, strengthening its clinical, academic and research capabilities until, over time, it is elevated into an Institute: a destination in its clinical discipline, a generator of published evidence, a trainer of national and international leaders, and a partner sought after by industry, academia and governments. World-class in the fullest meaning of that phrase.”

The Orthopaedic and Rheumatology CoE builds on the establishment of the Heart & Lung Centre of Excellence at Johor Specialist Hospital and the Neuroscience & Stroke Centre of Excellence at Damansara Specialist Hospital 2, reinforcing KPJ Healthcare’s long-term strategy to establish 15 Centres of Excellence nationwide by 2030 under the KPJHS. Through its integrated hub model anchored by KPJ Penang Specialist Hospital together with KPJ Selangor Specialist Hospital, the Centre enables shared expertise, common clinical standards, coordinated research and multidisciplinary collaboration across the KPJ Health System, demonstrating how specialised care can be delivered through one integrated academic health system. This integrated approach also provides the platform to accelerate the convergence of artificial intelligence, genomics and value-based care in shaping the future of specialised healthcare delivery.

KPJ Penang is a 270-bed tertiary hospital supported by more than 50 resident consultants across over 20 medical specialties. The establishment of the Orthopaedic and Rheumatology CoE further strengthens the hospital’s role within the KPJHS. Through the Centre, patients benefit from greater access to advanced orthopaedic treatments that have demonstrated improved patient-reported outcomes and shorter hospital stays. Complementing these capabilities, KPJ Penang is also the first in the Northern Region to provide advanced wound care management and, in collaboration with KPJ Healthcare University, is developing Malaysia’s first AI-assisted remote telewound care programme.

ENDS

About KPJ Healthcare Berhad 

KPJ Healthcare operates 30 hospitals across Malaysia and four Ambulatory Care Centres, serving 3.3 million patients annually with 1,491 medical consultants. Nineteen hospitals are accredited by MSQH and four by JCI. As Malaysia’s first private healthcare provider to establish an Academic Health System, KPJHS integrates practice, education and research & innovation to drive clinical excellence and patient experience. Beyond hospitals, KPJ Healthcare operates Klinik Waqaf An-Nur (KWAN) clinics, dialysis centres and mobile clinics nationwide, and offers more than 40 academic programmes at KPJ Healthcare University (KPJU). KPJ Healthcare has been a constituent of the Bursa Malaysia FTSE4Good Index since 2016.

Thailand – Canada Pilot Carbon Capture in Cement Industry to Advance Net Zero 2050

By
Advertorial Desk
-

BANGKOK, THAILAND – Media OutReach Newswire – 3 August 2026 – Thai Cement Manufacturers Association (TCMA) is advancing Thailand–Canada collaboration by piloting carbon capture technology in the Thai cement industry. The initiative designates the “Saraburi Sandbox” as a low-carbon technology testbed, bringing together industry, government, academia, and global partners to support the transition to a low-carbon economy, while enhancing the long-term competitiveness of Thailand’s industrial sector.

นางสาวริเชลล์ บูร์กวง ปลัดกระทรวงการค้าและกา.jpeg

From Thailand–Canada Collaboration to Industrial-Scale Deployment

TCMA announced progress in its strategic Thailand–Canada partnership under the project “Decarbonization of the Cement and Concrete Sectors in Thailand.” As part of the initiative, a Mobile Carbon Capture Unit (MCCU) has been deployed in Thailand for the first time to test the technology’s performance in real industrial conditions within the cement sector.

The deployment of the MCCU marks a significant step in strengthening technological readiness for carbon capture—one of the key solutions for high-emission industries such as cement—while supporting the Thailand 2050 Net Zero Cement and Concrete Roadmap.

Dr. Chana Poomee, Honourary Chairman of TCMA and President of the ASEAN Federation of Cement Manufacturers (AFCM), stated that the project reflects Thailand’s strong commitment to driving industry toward Net Zero through international collaboration. TCMA serves as a central platform linking industry, government, academia, and global organizations to develop practical carbon reduction solutions.

“The transition to Net Zero for hard-to-abate sectors such as cement cannot be achieved in isolation. It requires policy support from the government, as well as international collaboration in technology, finance, and knowledge transfer to accelerate real-world implementation,” Dr. Chana said.

Connecting Technology and Investment Through Global Collaboration

The project is funded by the Government of Canada through Environment and Climate Change Canada (ECCC), with the United Nations Industrial Development Organization (UNIDO) serving as the implementing agency. The initiative aims to develop a technology and innovation ecosystem for decarbonizing Thailand’s cement and concrete industries.

Ms. Richelle Bourgouin, Deputy Minister of Trade and Export Development, Saskatchewan, Canada, noted that the collaboration highlights the power of integrating knowledge, technology, and innovation to support the transition toward a low-carbon economy.

“This partnership also opens opportunities to connect expertise in clean technology, research, and innovation between the two countries, enabling the development of practical solutions and fostering future trade and investment cooperation in Thailand and across ASEAN,” Ms. Richelle said.

A key outcome of the project is the deployment of the MCCU, developed by the Clean Energy Technologies Research Institute (CETRI) at the University of Regina, Canada. The unit will be tested in Thailand to evaluate its performance and applicability within the Thai cement industry.

“Saraburi Sandbox”: A PPP Model for Accelerating Low-Carbon Industry

Under the project, TCMA is collaborating with Chulalongkorn University to study and transfer knowledge on carbon capture technology while building human capacity. The MCCU will be rotated across cement plants operated by TCMA member companies in Saraburi province to test performance, collect technical data, and assess future investment pathways.

The “Saraburi Sandbox” serves as a Public-Private Partnership (PPP) platform, bringing together government, industry, academia, and international partners to pilot and scale carbon reduction technologies, while establishing investment models for a low-carbon economy.

The area is being developed as a prototype low-carbon city, integrating technology, infrastructure, standards, and investment frameworks to support Thailand’s long-term industrial transition.

Accelerating Readiness for a Low-Carbon Future

Dr. Chana emphasized that deploying the MCCU in Thailand represents an important step in enhancing technological and knowledge readiness, particularly in carbon capture technologies that are essential for industries facing significant decarbonization challenges.

Preparation must begin today, as the transition to Net Zero requires time for technological development, workforce readiness, and infrastructure buildout, alongside appropriate support mechanisms. This is especially important as global carbon measures—such as carbon pricing and emissions trading systems (ETS)—become increasingly stringent.

“The success of decarbonizing the cement industry depends on collaboration across all sectors to create an enabling ecosystem for investment and to accelerate the adoption of technologies at scale,” Dr. Chana said.

TCMA’s efforts not only reflect the Thai cement industry’s commitment to translating decarbonization plans into action, but also reinforce the importance of Thailand–Canada collaboration in advancing clean technologies and innovation in the industrial sector. This includes knowledge transfer, technology development, and expanding future investment partnerships.

This collaboration represents a key mechanism in laying the foundation for Thailand’s cement industry to remain competitive in a low-carbon economy, while accelerating progress toward Net Zero 2050 and strengthening Thailand’s role as a regional model for low-carbon industrial development in ASEAN.

Hashtag: #TCMA #สมาคมอุตสาหกรรมปูนซีเมนต์ไทย #CementActionToNetZero #CarbonCapture #MCCU #NetZero2050 #ไทยแคนาดา #ClimateTech #สระบุรีแซนด์บ็อกซ์

The issuer is solely responsible for the content of this announcement.

Hualien Summer Fun ONE PIECE: Every Stop is a Unique Hualien Adventure

By
Advertorial Desk
-

HUALIEN, Aug. 3, 2026 /PRNewswire/ — For the first time ever, the Hualien County Government has launched a crossover collaboration with the globally ultra-popular IP, ONE PIECE! The massive 15-meter-long Thousand Sunny has officially set sail for Liyu Lake in Shoufeng Township, becoming the biggest highlight of the event. Making a simultaneous debut are six all-new classic character installations, which are placed in combination with Hualien’s diverse local features:

  • Usopp at Hualien Railway Station, echoing the imagery of a new adventure setting off.
  • Zoro at the century-old General’s House (Chiang Chün Fu). Fusing Japanese architecture with cultural heritage, the site echoes the perseverance and conviction represented by Zoro.
  • Luffy at the bustling Dongdamen Night Market. Gathering Hualien’s local delicacies, it is a crucial hub for travelers to experience local flavors—something the food-loving Luffy could never miss.
  • Sanji at Sunrise Square. Boasting views of Hualien Fishing Harbor, it presents a rich marine culture and fresh ingredients, echoing Sanji’s vitality and passion.
  • Nami at Zhikaxuan Forest Park. Surrounded by lush greenery and ecological landscapes, the park provides a space for families to relax and experience nature.
  • Chopper at the event’s main venue, Liyu Lake in Shoufeng Township. Famous for its stunning lake and mountain scenery, the area offers a tourism atmosphere that is both for sightseeing and therapeutic healing, perfectly echoing Chopper’s character traits!

The Hualien County Government stated that the event will run until August 20. In addition to a stamp rally mission, the nighttime will feature spectacular water and light shows, starry sky fireworks displays, and world-class fire dance performances!

Information provided by the Hualien County Government
Information provided by the Hualien County Government

 

iRad Hospital Featured on CNN’s Meanwhile in Asia

By
Advertorial Desk
-

Spotlighting Macao’s Emerging Medical and Wellness Sector


MACAU SAR – Media OutReach Newswire – 3 August 2026 – iRad Hospital, a premier medical and wellness facility launched by Melco Resorts & Entertainment and iRad Group, was recently featured in a July 2026 episode of CNN’s internationally broadcast program Meanwhile in Asia. The program discussed Macao’s efforts to diversify its economy beyond gaming, spotlighting its medical and wellness tourism sector.

iRad Hospital at Studio City, Macau
iRad Hospital at Studio City, Macau

During the episode, CNN examined how destinations across Asia are seeking new growth avenues, noting Macao’s strategic push to develop a niche in medical tourism. The feature included a visit to iRad Hospital, which opened within a luxury integrated resort environment, and highlighted its proposition of allowing visitors to incorporate health screenings and aesthetic treatments into their leisure or family stays.

Located at Melco’s Studio City, iRad Hospital is the world’s first and Macao’s only integrated resort hospital. In partnership with iRad, Melco is playing a leading role in advancing Macao’s medical tourism development by integrating healthcare and wellness services with its world-class Forbes Five-star spa portfolio. The initiative aligns with Macao’s broader economic diversification objectives and contributes to strengthening the city’s appeal to high-value international visitors beyond gaming.

iRad Hospital offers advanced diagnostic imaging, wellness and preventive care, aesthetic medicine, executive health screening, and dedicated medical concierge services. Through partnerships with leading hospitals and institutions in Hong Kong, the United States and Korea, the hospital provides visitors with access to expanded specialty medical resources and healthcare options.

Mr. Lawrence Ho, Chairman & CEO of Melco Resorts & Entertainment, said, “Macao’s next phase of development will be defined by quality, innovation, and diversification. As the leading integrated resort operator, we are committed to advancing the evolution of the integrated resort model beyond traditional hospitality—integrating culture, wellness, and high‑value services that strengthen the city’s long‑term competitiveness. Through initiatives such as iRad Hospital at Studio City, Melco is helping shape the development of integrated medical and wellness tourism and enhancing Macao’s visibility as a diversified international destination.”

Hashtag: #melco #iRadHospital #iRad #StudioCity #medicaltourism #wellness





Wechat: 新濠博亚娱乐

The issuer is solely responsible for the content of this announcement.

About Melco Resorts & Entertainment Limited

The Company, with its American depositary shares listed on the Nasdaq Global Select Market (Nasdaq: MLCO), is a developer, owner and operator of integrated resort facilities in Asia and Europe. The Company currently operates City of Dreams () and Altira Macau (), integrated resorts located in Cotai and Taipa, Macau, respectively. In addition, the Company operates Studio City (), a cinematically-themed integrated resort in Cotai, Macau. In the Philippines, the Company operates and manages City of Dreams Manila (), an integrated resort in the Entertainment City complex in Manila. In Europe, the Company operates City of Dreams Mediterranean, an integrated resort in Limassol, in the Republic of Cyprus (). In South Asia, the Company manages the Nüwa hotel at City of Dreams Sri Lanka (), an integrated resort in Colombo, Sri Lanka. For more information about the Company, please visit.

The Company is majority owned by Melco International Development Limited, a company listed on the Main Board of The Stock Exchange of Hong Kong Limited, which is in turn majority owned and led by Mr. Lawrence Ho, who is the Chairman, Executive Director and Chief Executive Officer of the Company.

About iRad – Hong Kong’s largest MRI diagnostic services provider

Established in 2006, iRad is a trusted leader in diagnostic radiology across Hong Kong. As at 2024, iRad was the largest MRI diagnostic services provider in Hong Kong by revenue and by the number of MRI scanners. Focused on delivering high-quality imaging services and exceptional patient care, the Group’s strong and extensive client base includes the Government of the Hong Kong SAR, as well as other high-profile medical groups, corporations, private doctors and NGOs. Meanwhile, iRad Hospital is the first and largest private medical imaging and examination service provider within an integrated resort in Macau, making iRad Group the first medical imaging group in the world to offer comprehensive private imaging and examination services, including MRI and CT services, to the integrated resort industry.

Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination

By
Advertorial Desk
-

-Initiated global Phase III program for oral small molecule GLP-1, ASC30, which will enroll approximately 4,600 participants with obesity or overweight across two pivotal trials in the U.S., Europe, and Canada.

-Positive preclinical data in non-human primates announced for first-in-class once-daily oral small molecule GLP-1/GIP/amylin fixed-dose combination.

-Industry leading one-pill once-daily oral small molecule portfolio for obesity and other metabolic diseases: five programs spanning GLP-1, GIP, and amylin targets, alone and in fixed-dose combinations.

-Sufficient cash on hand to support operations into 2029, beyond the expected submission of a New Drug Application (NDA) in the U.S. by the end of 2028 and a Marketing Authorisation Application (MAA) in Europe in early 2029 for ASC30.

HONG KONG, Aug. 3, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces once-daily oral small molecule GLP-1 (ASC30) has received Phase III clearance from the U.S. Food and Drug Administration (FDA). ASC30 is the primary pillar of Ascletis’ oral small molecule obesity portfolio. The Company has initiated a global Phase III program for ASC30 chronic weight management indication consisting of two pivotal global Phase III, multicenter, randomized, double-blind, placebo-controlled trials (AURORA-1 NCT07743463 and AURORA-2 NCT07743450) in a total of approximately 4,600 participants with obesity or overweight in the U.S., Europe, and Canada. The two pivotal studies will investigate the long-term efficacy, safety, and tolerability of three maintenance doses (20 mg, 40 mg and 60 mg) of once-daily oral ASC30 compared with placebo in participants with obesity or overweight without type 2 diabetes (AURORA-1) and in participants with obesity or overweight with type 2 diabetes (AURORA-2). The treatment duration of both AURORA-1 and AURORA-2 are 72 weeks, with titrations of 12 weeks, 16 weeks and 20 weeks for 20 mg, 40 mg and 60 mg maintenance dose cohorts, respectively. The Company expects to announce topline data from the ASC30 Phase III program in the third quarter of 2028, with a U.S. FDA New Drug Application (NDA) filing expected by the end of 2028 and a European Medicines Agency (EMA) Marketing Authorisation Application (MAA) filing expected in early 2029. If approved by the respective regulatory authorities in the U.S. and Europe, this will make ASC30 potentially the second oral small molecule GLP-1 approved in the U.S. and Europe after orforglipron. The Company has sufficient cash on hand to support operations into 2029, beyond the expected submission of an NDA and an MAA for ASC30.

Ascletis also announces positive data for its first-in-class once-daily oral small molecule GLP-1/GIP/amylin triple agonist fixed-dose combination (FDC). The addition of this triple agonist FDC gives Ascletis a highly comprehensive and advanced oral small molecule portfolio for the treatment of obesity and other metabolic diseases (Table 1). The portfolio includes a best-in-class Phase III once-daily oral small molecule GLP-1, a first-in-class once-daily oral small molecule GLP-1/GIP dual agonist FDC (the first tirzepatide-like oral small molecule combination), a first-in-class once-daily oral small molecule GLP-1/GIP/amylin triple agonist FDC (the first oral tirzepatide+eloralintide-like small molecule combination), and a first-in-class once-daily oral small molecule eloralintide-like selective amylin receptor agonist (SARA). This comprehensive portfolio places Ascletis in a unique competitive position to significantly expand the population that can be treated with oral agents.

Table 1. Ascletis Once-Daily Oral Small Molecule Portfolio

Target

Drug Candidate

Development Status

GLP-1R

ASC30

Phase III

GLP-1R/GIPR

ASC30_48FDC

IND Filing 4Q2026

GLP-1R/GIPR/amylin receptor
(SARA)

ASC30_48_39FDC

IND Filing 4Q2026

Amylin receptor (SARA)

ASC39

IND Filing 3Q2026

GLP-1R/amylin receptor (SARA)

ASC30_39FDC

IND Filing 3Q2026

Notes: FDC: fixed-dose combination; SARA: selective amylin receptor agonist.

Oral Small Molecule Triple Agonist Combination (GLP-1/GIP/Amylin)

Ascletis’ first-in-class once-daily oral small molecule triple agonist FDC targeting GLP-1, GIP, and amylin (SARA) (ASC30_48_39FDC) demonstrated a GIPR agonist (ASC48) dose-dependent, statistically significant body weight reduction of up to 15.2% in non-human primates (NHPs) after seven-day treatment. This represents an up to 120% greater relative body weight reduction compared to oral dual agonist FDC targeting GLP-1R and amylin receptor (SARA) (ASC30_39FDC) (Table 2). The data suggest that GIP component (ASC48) is critical to ASC30_48_39FDC triple agonist. ASC30_48_39FDC is the oral small molecule triple agonist equivalent to injectable triple agonist peptides like tirzepatide+eloralintide which demonstrated a 29% reduction in body weight in humans at week 32 in a recently disclosed study [1].

Table 2. Once-Daily Oral Administration of ASC30_48_39FDC for Seven Consecutive Days in Non-Human Primates (NHPs)

Group

Dosing

Total body weight change
from baseline

ASC30_39FDC

(GLP-1R/amylin receptor
(SARA))

2 mg/kg ASC30

and 0.1 mg/kg ASC39

PO, QD

-6.9 %

ASC30_48_39FDC

(GLP-1R/GIPR/amylin
receptor (SARA))

2 mg/kg ASC30,

1 mg/kg ASC48,

and 0.1 mg/kg ASC39

PO, QD

-12.1%

(p < 0.05 vs ASC30_39FDC)

2 mg/kg ASC30,

2 mg/kg ASC48,

and 0.1 mg/kg ASC39

PO, QD

-15.2%

(p < 0.01 vs ASC30_39FDC)

Notes: FDC: fixed-dose combination; SARA: selective amylin receptor agonist; PO: oral administration; QD: once daily.

Oral Small Molecule Eloralintide-like SARA

Ascletis’ first-in-class once-daily oral small molecule eloralintide-like SARA (ASC39) is the second pillar of Ascletis oral small molecule obesity portfolio. ASC39 demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models (Press Release). ASC39 was 40-fold more selective for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR), which is comparable to the 60-fold greater selectivity of eloralintide in the same preclinical model. Once-daily oral administration of 5 mg/kg ASC39 for six consecutive days in the diet-induced obese rats produced a weight loss of 6.0%, similar to eloralintide at 5.0% (Table 3). ASC30_39FDC, a GLP-1/amylin dual agonist FDC, is expected to be the first FDC of this type to enter the clinic in the fourth quarter of 2026.

Table 3. Once-Daily Oral Administration of ASC39 for Six Consecutive Days Compared to Eloralintide SQ in Obese Rats

Group

Dosing

Total body weight change from baseline

Obese rats treated with eloralintide

3 nmol/kg,

SQ, Q3D

-5.0 %

Obese rats treated with ASC39
(amylin receptor (SARA))

5 mg/kg,
PO, QD

-6.0 %

Notes: Obese rats: diet-induced obese rats; SQ: subcutaneous; Q3D: once every 3 days; PO: oral administration; QD: once daily.

Oral Small Molecule Dual Agonist Combination (GLP-1/GIP)

Ascletis’ first-in-class once-daily oral dual FDC targeting GLP-1R and GIPR (ASC30_48FDC) demonstrated a 10.5% body weight reduction in non-human primates after eight-day treatment. This represents a 52% greater relative body weight reduction compared to ASC30 monotherapy (Press Release). ASC48, a first-in-class oral small molecule GIPR agonist, in a head-to-head in vitro study versus tirzepatide, demonstrated an EC50 of 1 pM in the hGIPR cyclic adenosine monophosphate (cAMP) activation assay, exhibiting greater potency than tirzepatide (EC50 = 3 pM). ASC30_48FDC represents the oral small molecule dual agonist equivalent to injectable dual agonist peptides like tirzepatide. Tirzepatide demonstrated up to a 20.9% reduction in body weight in humans as reported in the tirzepatide package insert[2].

Table 4. Once-Daily Oral Administration of ASC30_48FDC for Eight Consecutive Days in Non-Human Primates (NHPs)

Group

Dosing

Total body weight change from
baseline

ASC30 (GLP-1R)

2 mg/kg

PO, QD

-6.9 %

ASC30_48FDC

(GLP-1R/GIPR)

2 mg/kg ASC30 and

5 mg/kg ASC48

PO, QD

-10.5 %

Notes: FDC: fixed-dose combination; PO: oral administration; QD: once daily.

“Following recent positive end-of-Phase II feedback received from the FDA for ASC30, we are excited to have initiated the global Phase III program of ASC30, the primary pillar of our one-pill once-daily oral small molecule obesity portfolio.” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “ASC30 (GLP-1), ASC48 (GIP) and ASC39 (amylin SARA) are small molecules with different physical-chemical properties. We have overcome multiple challenges during the development of fixed-dose combinations of these molecules. The new data for our first-in-class oral small molecule triple agonist fixed-dose combination (GLP-1/GIP/amylin) reinforces our industry-leading, comprehensive and differentiated portfolio of one-pill once-daily oral small molecules for the treatment of obesity and other metabolic diseases.”

[1] Eli Lilly and Company. Safety, tolerability, pharmacokinetics and pharmacodynamics of eloralintide and tirzepatide co-administered as once-weekly subcutaneous injections [Abstract accepted for presentation at EASD 2026]

[2] ZEPBOUND (tirzepatide) injection, for subcutaneous use [US Prescribing Information]. Indianapolis, IN: Eli Lilly and Company. Section 14.1, Table 2 (Changes in Body Weight at Week 72 in Study 1)

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48 FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39 FDC, a once-daily oral small molecule triple agonist, a fixed dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily small molecule, ASC30_39 FDC, a once-daily oral small molecule dual agonist, a fixed dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36, an amylin peptide, designed to be administered once monthly to once quarterly subcutaneously and once daily orally, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, ASC36_35 FDC, a once-monthly subcutaneous triple peptide agonist, a fixed combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, designed to be administered once monthly subcutaneously and once daily orally, and ASC36_37 FDC, a once-monthly subcutaneous quadruple peptide agonist, a fixed dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com. 

Contact:
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com 

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com 
ir@ascletis.com 

WATERBOMB SEOUL 2026 Successfully Concludes as CSTS and PremierX™ Help Power the Festival’s Global Future

By
Advertorial Desk
-

SEOUL, South Korea, Aug. 3, 2026 /PRNewswire/ — WATERBOMB SEOUL 2026 successfully concluded an unforgettable three-day celebration of music, entertainment and immersive fan experiences, bringing together tens of thousands of fans from Korea and around the world for one of Asia’s most anticipated summer festivals. Held at the KINTEX Outdoor Global Stage in Goyang, the event showcased the unique combination of live music and signature water-themed attractions that have made Waterbomb a global cultural phenomenon.

Credit: Waterbomb
Credit: Waterbomb

Fans experienced a diverse lineup of some of the biggest names in K-pop, hip-hop and electronic dance music with performances by global and regional stars including Jay Park, ZICO, KARINA, Taemin, Sunmi, and Shownu & Hyungwon of MONSTA X, among others.

Widely regarded as Korea’s premier water-themed music festival, Waterbomb once again delivered its signature blend of music, energy and audience participation. Beyond the performances, attendees took part in large-scale water battles and immersive interactive experiences that have become synonymous with the festival. Its unique format continues to distinguish it from other music events, creating an environment where audiences are participants rather than simply spectators.

The Seoul 2026 edition also marked a significant milestone for CSTS Enterprises and its PremierX brand, whose involvement reflects CSTS Group’s growing commitment to experiential live entertainment. Earlier this year, CSTS announced its strategic collaboration with MADEONE Corp., owner and operator of Waterbomb, to support continued development of the festival in Seoul and around its international expansion.

Through the partnership, CSTS and PremierX contributed their expertise in hospitality, entertainment strategy, audience engagement and brand development, helping reinforce Waterbomb’s position as one of the most influential festival properties from Asia. The successful execution of Waterbomb Seoul 2026 further demonstrates the strength of the partnership and the growing international appeal of the Waterbomb brand.

“Waterbomb is much more than a music festival. It is a global lifestyle and cultural platform that connects audiences through unforgettable experiences,” said Winnie Chan, General Manager, CSTS Integrated Marketing. “The success of Waterbomb Seoul 2026 highlights the power of collaboration between CSTS, PremierX and MADEONE, and reinforces our shared vision of bringing this iconic entertainment experience to audiences around the world.”

As the final water cannons fired and performances concluded, Waterbomb Seoul 2026 closed another landmark chapter in the festival’s history, setting the stage for continued international growth. Building on this momentum, CSTS and PremierX look forward to supporting the next phase of Waterbomb’s expansion, bringing the festival’s unique blend of music, community and immersive entertainment to new audiences across Asia and beyond.

Credit: Waterbomb
Credit: Waterbomb

About WATERBOMB

WATERBOMB is South Korea’s globally recognized water-themed music festival, combining performances from leading K-pop, hip-hop and EDM artists with large-scale interactive water experiences. Since its launch in 2015, the festival has expanded beyond Korea to become one of Asia’s most recognizable live entertainment brands.

About CSTS Enterprises

CSTS Enterprises is an integrated media, entertainment, sports, and travel technology group. The company develops and partners with intellectual properties and brands to deliver compelling experiences that connect with local and regional audiences across the world. In addition to its own initiatives, including Generation C and PremierX, it collaborates with international IPs such as the FIFA World Cup, Formula 1, and Waterbomb.

CSTS integrates experiential marketing, tourism, data, and technology to deliver connected audience experiences. The company engages consumers across physical events and digital channels, working with clients to execute at scale across markets, turning complex activations into co-ordinated, measurable outcomes.

About MADEONE Corp.

MADEONE Corp. is a Seoul-based creative production house and entertainment agency specializing in the development and execution of leading festival experiences. Guided by the philosophy, “If our hearts don’t beat, we cannot thrill anyone,” MADEONE has redefined the music festival landscape through its flagship brand, WATERBOMB®, integrating music, performance, and audience participation into a new entertainment paradigm. In addition to festival production, the company provides theatrical services and manages talent in the arts and entertainment. MADEONE continues to expand its global footprint through international editions of its high-energy events.


AutoFlight Showcases Advanced Air Mobility During Games of the Future 2026 in Astana, Kazakhstan

By
Advertorial Desk
-
  • AutoFlight completes first Air Taxi Demonstration Flight in Astana
  • Advanced Air Mobility showcased during Games of the Future 2026
  • Partnership with AAAG supports commercial deployment in Kazakhstan

ASTANA, Kazakhstan, Aug. 3, 2026 /PRNewswire/ — AutoFlight, a global leader in Advanced Air Mobility (AAM), together with its strategic partner Alatau Advance Air Group Ltd. (AAAG), is showcasing Advanced Air Mobility through live electric vertical takeoff and landing (eVTOL) demonstration flights and themed activities during the Games of the Future 2026 in Astana, Kazakhstan. https://www.linkedin.com/feed/update/urn:li:activity:7486683825448787968


AutoFlight Showcases Advanced Air Mobility During Games of the Future 2026 in Astana, Kazakhstan

AutoFlight successfully completed its Air Taxi Demonstration Flight on 24 July, with the ton-class eVTOL aircraft continuing to be showcased throughout the Games of the Future 2026 as part of the official public exhibition. https://www.youtube.com/watch?v=jxQ2uT9v3h0

As one of the world’s leading international phygital tournaments, Games of the Future 2026 brings together more than 800 competitors from over 50 countries across eight disciplines, combining elite physical competition with digital gaming. Against this global stage, AutoFlight’s showcase demonstrates how Advanced Air Mobility is becoming part of the future of transportation.

The Astana demonstration follows AutoFlight’s successful first eVTOL flight in Alatau City in May 2026 and reflects the company’s continued commitment to supporting the development of Advanced Air Mobility in Kazakhstan. Through its partnership with AAAG, AutoFlight is working to accelerate commercial deployment by supporting aviation innovation, smart infrastructure and regional connectivity.

“The demonstration flights in Astana are not a standalone event but part of a systematic effort to introduce urban air mobility in Kazakhstan. The country is steadily building a comprehensive ecosystem: the necessary legislation has been adopted, infrastructure development is underway, and international cooperation with leading global companies continues to expand. Our goal is to make innovative air transport an integral part of Kazakhstan’s transportation system,” said Sergey Khegay, Chief Executive Officer of AAAG.

“We envision our large-scale eVTOL technology transforming this region across multiple dimensions—from urban air mobility and intercity travel to aerial sightseeing, logistics and emergency response,” Kellen Xie, Senior Vice President of AutoFlight emphasized, “These applications represent not merely technological possibilities but a new paradigm of sustainable, zero-emission transportation for Central Asia.”

As AutoFlight continues expanding its global footprint, the company remains committed to working with governments, regulators and strategic partners worldwide to accelerate the commercialization of eVTOL technology and unlock new opportunities for sustainable air transportation.

WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers’ Products and CRDMO Model

By
Advertorial Desk
-

SHANGHAI, Aug. 3, 2026 /PRNewswire/ — WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first half ending June 30, 2026 (“Reporting Period”). The Company raised its full-year guidance, citing strong performance across revenue, profit, and cash flow driven by the greater success of multiple customers’ products and its unique integrated CRDMO platform.

Financial Highlights

  • H1 2026 total revenue reached RMB 28.90 billion, up 38.9% YoY; revenue from Continuing Operations[2] up 48.0% YoY.
  • Adjusted non-IFRS gross profit margin expanded 9.4 percentage points (pts) YoY to 53.9%.
  • Adjusted non-IFRS net profit up 83.2% YoY to RMB 11.57 billion; adjusted non-IFRS net profit margin up 9.7pts YoY to 40.0%; adjusted non-IFRS diluted EPS[3] up 78.2% YoY to RMB 3.92.
  • Net profit per CAS[4] up 29.4% YoY to RMB 11.08 billion; diluted EPS up 25.8% YoY to RMB 3.76.
  • Backlog for Continuing Operations up 25.2% YoY to RMB 66.43 billion as of June 30, 2026.
  • Adjusted operating cash flow rose 41.3% YoY to RMB 9.98 billion.

Management Comment

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, “As a dedicated enabler of the industry, we truly appreciate that our achievements are rooted in the exceptional performance of our customers. Driven by the greater success of multiple customers’ products, our unique CRDMO model, and our global team’s perseverance for excellence, we delivered strong growth across revenue, profit, and cash flow in H1 2026, with our backlog for Continuing Operations reaching RMB 66.4 billion. We have therefore raised all of our 2026 guidance metrics and further accelerated our global capacity expansion.”

“Recently, the U.S. Department of Defense included the Company on its 1260H list. This erroneous designation is not supported by facts or law. We have taken legal action to protect the interests of our customers, employees, and shareholders. We believe that the facts will prevail after an objective and fair judicial review of this ongoing litigation.”

“As technology advancements and science innovations continue to emerge, WuXi AppTec remains steadfast in ‘doing the right thing and doing it right.’ We will relentlessly enable global innovators and realize our vision that ‘every drug can be made and every disease can be treated.'”

Sustainability, and Quality Compliance

WuXi AppTec maintained the highest “AAA” MSCI ESG rating in 2026. Meanwhile, the Company successfully completed 465 quality audits and inspections[5] conducted by global customers, regulatory authorities, and independent third parties, as well as 21 information security audits by global customers in H1 2026, all with no critical findings. Twenty main sites are now ISO/IEC 27001 certified.

Shareholder Returns

The Company distributed its 2025 annual cash dividend totaling RMB 4.71 billion[6]. Following the first interim dividend in 2025, the Board has proposed a further increase in the 2026 interim cash dividend to shareholders of RMB 5.10 per 10 shares (approximately RMB 1.5 billion in total).

2026 Full-Year Outlook

Driven by the greater success of multiple customers’ products, our unique CRDMO model, and management and execution excellence, the Company has raised full-year guidance.

  • 2026 total revenue target raised to RMB 58.5-60.5 billion (previously RMB 51.3-53.0 billion), with Continuing Operations revenue growing 35-39% YoY (previously 18-22%).
  • The Company is confident in maintaining a stable and resilient adjusted non-IFRS net profit margin in 2026.
  • 2026 capex guidance raised to RMB 7.5-8.5 billion (previously RMB 6.5-7.5 billion) to support accelerated global capacity expansion, including initiation of the new Changzhou site ahead of schedule.
  • As a result, 2026 adjusted free cash flow raised to RMB 13.5-14.5 billion (previously RMB 10.5-11.5 billion).

[1] This guidance constitutes forward-looking statements.

[2] As disclosed in the 2026 Interim Report, Continuing Operations include WuXi Chemistry, WuXi Testing, WuXi
Biology and Others; historical data has been adjusted accordingly.

[3] In H1 2025 and H1 2026, WuXi AppTec’s weighted average number of ordinary shares for the purpose of
calculating diluted EPS was 2,897,449,552 and 2,949,022,327, respectively.

[4] Net profit attributable to the owners of the Company (“Net Profit”) is prepared in accordance with China Accounting
Standards for Business Enterprises (“CAS”).

[5] Including 433 audits by customers, 31 inspections by regulatory authorities, and 1 audit by independent third parties.

[6] This excludes the RMB 1.03 billion already paid as the 2025 interim dividend.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.

This press release provides a summary of the results and does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For relevant information, please refer to the Company’s disclosure documents and information on the Shanghai Stock Exchange (“SSE”), the Stock Exchange of Hong Kong Limited (“HKEX”) and the Company’s website. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

Unless otherwise stated, all financials disclosed in this press release are prepared based on IFRS. The currency is RMB.

The 2026 Interim Report of the Company has not been audited.

Forward-Looking Statements

This press release may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks and uncertainties including, but not limited to, the effective competitiveness of our services, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients’ intellectual property, industry competition and regulation, the international geopolitical environment, legislative restrictions and judicial proceedings, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management or an undertaking by WuXi AppTec Co., Ltd. (“WuXi AppTec” or the “Company”) to our investors. ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and is based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this press release to reflect future events or circumstances, except as required under applicable law.

Use of Adjusted Non-IFRS Financial Measures

To supplement the Company’s IFRS consolidated financial statements, we also provide adjusted non-IFRS gross profit, adjusted non-IFRS net profit attributable to the owners of the Company (“Adjusted Non-IFRS Net Profit”), adjusted non-IFRS diluted earnings per share (“Adjusted Non-IFRS Diluted EPS”), adjusted operating cash flow and adjusted free cash flow. These measures are not required by, or presented in accordance with IFRS.

We believe that the adjusted non-IFRS financial measures used in this press release are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. The management of the Company believes such adjusted non-IFRS financial measures are widely accepted and adopted in the industry in which the Company operates. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation, or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

 

 

1...256257258...6,639Page 257 of 6,639